학술논문

Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial
Document Type
Article
Source
In: European Journal of Cancer. (European Journal of Cancer, July 2024, 205)
Subject
Language
English
ISSN
18790852
09598049